These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19151603)

  • 1. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
    Sistonen J; Fuselli S; Palo JU; Chauhan N; Padh H; Sajantila A
    Pharmacogenet Genomics; 2009 Feb; 19(2):170-9. PubMed ID: 19151603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus.
    Semiz S; Dujic T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Marc J; Causevic A
    Bosn J Basic Med Sci; 2010 Nov; 10(4):287-91. PubMed ID: 21108610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of CYP2D6, CYP2C9 and CYP2C19 genotypes with Tag-It mutation detection assays.
    Melis R; Lyon E; McMillin GA
    Expert Rev Mol Diagn; 2006 Nov; 6(6):811-20. PubMed ID: 17140368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
    Kirchheiner J; Müller G; Meineke I; Wernecke KD; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
    Skadrić I; Stojković O
    Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.
    Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
    Mol Diagn Ther; 2014 Apr; 18(2):229-36. PubMed ID: 24338437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
    Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
    Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
    Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
    Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of CYP450 testing in the clinical setting.
    Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
    Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
    Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
    Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
    Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
    Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
    Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
    J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.